文献速递血栓与止血

重型伴抑制物血友病A患者出现艾美赛珠单抗中和性抗药抗体:新病例及详细实验室评估

Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation.
PubMed 文献 · J Thromb Haemost · 2020-07-06

本文报告一例重型伴抑制物血友病A患者在接受艾美赛珠单抗治疗后出现中和性抗药抗体,并进行了全面的特殊凝血实验室检测。文中提及HAVEN临床试验项目中抗药抗体伴中和潜力的发生率为0.75%,且自该药获批以来尽管已用于数千例患者,尚无进一步此类抗体报告。

要点

  • 重型伴抑制物血友病A患者可对艾美赛珠单抗产生中和性抗药抗体。
  • HAVEN临床试验项目中抗药抗体伴中和潜力的发生率为0.75%。
  • 该病例进行了详尽的特殊凝血实验室评估。

核心结论

  • 本文报告一例重型伴抑制物血友病A患者出现对艾美赛珠单抗的中和性抗药抗体,并进行了广泛的特殊凝血实验室检测。

研究设计与样本

  • 病例报告,描述一例重型伴抑制物血友病A患者及其实验室评估。

主要发现

  • 该患者为重型伴抑制物血友病A,产生了对艾美赛珠单抗的中和性抗药抗体。
  • HAVEN临床试验项目中抗药抗体伴中和潜力的发生率为0.75%。
  • 自艾美赛珠单抗获批以来,尽管已用于数千例患者,尚无进一步此类抗体报告。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemophilia A is an inherited bleeding disorder characterized by deficiency of the coagulation protein factor VIII. Development of clotting factor concentrates has resulted in an excellent prognosis for this historically fatal disease. However, neutralizing antidrug antibodies to factor concentrates can develop, complicating management and worsening the prognosis, and thus creating an unmet need for novel therapies. One such agent is emicizumab, a bispecific monoclonal antibody which mimics the function of factor VIII. Collectively across the HAVEN clinical trial program, the rate of antidrug antibodies with neutralizing potential was 0.75%. Since its licensure, there have been no further reports of such antibodies, despite its use in thousands of patients. In this report, we describe a patient with severe hemophilia A with inhibitors who developed a neutralizing antidrug antibody to emicizumab, for whom we performed extensive testing in the special coagulation laboratory.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Harkins Druzgal C, Kizilocak H, Brown J, et al. Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation. J Thromb Haemost. 2020. PMID: 32544268. doi:10.1111/jth.14957

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。